=== PAGE 6 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Page 6

Nicole Van de Vaarst
Mirati Therapeutics Inc., a Bristol Myers Squibb Co.
NDA 216340/MA 166

communications (with the 2253 submission date) for Krazati that contain representations like
those described above, and explaining your plan for the timely discontinuation of such
communications, or for ceasing distribution of Krazati.

If you believe that your products are not in violation of the FD&C Act, please include in your
submission to us your reasoning and any supporting information for our consideration within
15 working days from the date of receipt of this letter.

The concerns discussed in this letter do not necessarily constitute an exhaustive list of
potential violations. It is your responsibility to ensure compliance with each applicable
requirement of the FD&C Act and FDA implementing regulations.

Please direct your response to the undersigned at the **Food and Drug Administration,**
**Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-**
**B Ammendale Road, Beltsville, Maryland 20705-1266.** A courtesy copy can be sent by
facsimile to (301) 847-8444. Please refer to MA 166 in addition to the NDA number in all
future correspondence relating to this particular matter. All correspondence should include a
subject line that clearly identifies the submission as a Response to Untitled Letter. You are
encouraged, but not required, to submit your response in eCTD format. All correspondence
submitted in response to this letter should be placed under eCTD Heading 1.15.1.6.
Additionally, the response submission should be coded as an Amendment to eCTD
Sequence 5163 under NDA 216340. Questions related to the submission of your response
letter should be emailed to the OPDP RPM at CDER-OPDP-RPM@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Kelle Caruso, PharmD, BCPS
Regulatory Review Officer
Division of Advertising & Promotion Review 1
Office of Prescription Drug Promotion

{See appended electronic signature page}

Rachael Conklin, MS, RN, RAC
Team Leader
Division of Advertising & Promotion Review 1
Office of Prescription Drug Promotion

Reference ID: 5423579
